Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Wright Medical Group's Total Stockholders Equity for the quarter that ended in Jun. 2015 was €188.2 Mil. Wright Medical Group's Total Assets for the quarter that ended in Jun. 2015 was €1,044.1 Mil.
Therefore, Wright Medical Group's Equity to Asset Ratio for the quarter that ended in Jun. 2015 was 0.18.
The historical rank and industry rank for Wright Medical Group's Equity-to-Asset or its related term are showing as below:
FRA:WM3'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.4 Med: 0.62 Max: 0.83
Current: 0.18
During the past 13 years, the highest Equity to Asset Ratio of Wright Medical Group was 0.83. The lowest was -0.40. And the median was 0.62.
FRA:WM3's Equity-to-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.65
vs FRA:WM3: 0.18
Wright Medical Group Equity-to-Asset Historical Data
The historical data trend for Wright Medical Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Wright Medical Group's Equity-to-Asset
For the Medical Devices subindustry, Wright Medical Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wright Medical Group's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Wright Medical Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Wright Medical Group's Equity-to-Asset falls into.
Wright Medical Group Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Wright Medical Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wright Medical Group (FRA:WM3) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Wright Medical Group Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Wright Medical Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Wright Medical Group (FRA:WM3) Business Description
Wright Medical Group Inc, through Wright Medical Technology, Inc. and other operating subsidiaries, is a specialty orthopaedic company, that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients' lifestyles. The Company provides surgical solutions for the foot and ankle market and markets its products in over 60 countries. Its business includes products that are used in foot and ankle repair, upper extremity products, and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. Extremity hardware includes implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow and shoulder, which it generally refer to as either foot and ankle or upper extremity products. The Company's manufacturing and warehousing operations are located in Arlington, Tennessee. Outside the U.S., The Company has distribution and administrative facilities in Amsterdam, the Netherlands, and sales and distribution offices in Canada, Australia, and Europe. The Company operates its continuing operations as one reportable segment and offer products in extremity reconstruction and biologics. The Company's products include CHARLOTTE, CLAW II, DARCO, EVOLVE, MICRONAIL, GRAFTJACKET, OSTEOSET. Its competitors include major companies in the orthopaedic and biologics industries, as well as academic institutions and other public and private research organizations that continue to conduct research, seek patent protection and establish arrangements for commercializing products. The Company's products are strictly regulated by the FDA under the Food, Drug, and Cosmetic Act. Some of its products are also regulated by state agencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:WM3 has been successfully added to your 